source
- Windward Bio raises $225 million in IPO to fund Chinese-sourced respiratory drug programWindward Bio, backed by Sanofi, completed its initial public offering at the $225 million target, selling 10.3 million shares at $17 each. The proceeds will be used to advance two respiratory drug…
- Gate Bioscience eyes clinic trials with molecular gate drugs, backed by expanded $870M Lilly partnershipGate Bioscience is developing small-molecule drugs that block the Sec61 channel, preventing disease-causing proteins from entering cells and leading to their degradation. The company's first discl…